New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 13, 2012
10:24 EDTAMT, ABC, CELG, ITW, NOK, PPL, JBHTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Tower (AMT) downgraded to Neutral from Overweight at Piper Jaffray... AmerisourceBergen (ABC) downgraded to Equal Weight from Overweight at Morgan Stanley... Celgene (CELG) downgraded to Hold from Buy at Auriga... Illinois Tool Works (ITW) downgraded to Underweight from Equal Weight at Morgan Stanley... Nokia (NOK) downgraded to Equal Weight from Overweight at Barclays... PPL Corp. (PPL) downgraded to Buy from Conviction Buy at Goldman... J.B. Hunt (JBHT) downgraded to Neutral from Buy at Sterne Agee.
News For AMT;ABC;CELG;ITW;NOK;PPL;JBHT From The Last 14 Days
Check below for free stories on AMT;ABC;CELG;ITW;NOK;PPL;JBHT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 28, 2014
15:47 EDTITWNotable companies reporting before tomorrow's open
Subscribe for More Information
14:39 EDTITWIllinois Tool Works technical notes ahead of earnings
The shares have turned in a flat performance in the last three months, but have traded in a relatively wide range. The peak of price for that range was at $89.50, the 52-week high with $84 the low. Price was last at $84.74. With the recent decline from peak, the stock has broken the longer-term uptrend in place since the lows of February. The 10-day and 50-day moving averages have bearishly crossed, indicating a loss of upside momentum. On worse than anticipated results or guidance, the 200-day moving average at $82.49 would be a first and important test of support. A breakdown below the 200-day would be bearish for the long-term and is a sell signal in many trading systems with long time frames. Additional support below $82.49 would be at $79.47 and $76.25. On better than expected news, resistance would be at $87, the 50-day moving average. It would take a move back above the 50-day to put the shares back on a bullish footing. Next resistance would be at $89.50, the life high for the stock. Any move above that level would have no resistance to encounter, with $90 and $92.50 as possible objectives.
July 25, 2014
10:55 EDTABCHigh option volume stocks
Subscribe for More Information
09:28 EDTABCCardinal Health has good read through from AmerisourceBergen, says Sterne Agee
Sterne Agee believes that AmericansourceBergen's (ABC) beat and raise results bode well for Cardinal Health (CAH). The firm keeps a Buy rating on Cardinal.
08:51 EDTPPLPPL Corp. multiple likely to rise, says Argus
After PPL announced an agreement with Riverstone Holdings to combine their merchant power businesses into a new publicly traded independent power producer, Argus thinks the regulated businesses retained by PPL will support steady earnings and dividend growth. The firm thinks that investors will respond by awarding the stock higher multiples. It keeps a Buy rating on the shares.
07:06 EDTCELGCelgene shares should recover, says Cantor
Subscribe for More Information
July 24, 2014
12:20 EDTCELGCelgene price target raised to $115 from $85 at Piper Jaffray
Subscribe for More Information
11:55 EDTNOKNokia denied writ of mandamus in patent fight with InterDigital
Subscribe for More Information
07:45 EDTCELGCelgene reports Q2 VIDAZA sales decreased 28%
Subscribe for More Information
07:43 EDTCELGCelgene reports Q2 ABRAXANE sales increased 39%
Subscribe for More Information
07:42 EDTCELGCelgene reports Q2 REVLIMID sales increased 15%
Subscribe for More Information
07:34 EDTCELGCelgene raises FY14 adjusted EPS view to $3.60-$3.65 from $3.50-$3.60
Consensus is $3.67. Raises FY14 revenue view to $7.6B from $7.5B, consensus $7.54B. Sees Revlimid net product sales $4.95B from preview $4.9B-$5B range. Sees Abraxane net product sales $850M-$900M.
07:32 EDTCELGCelgene reports Q2 adjusted EPS 90c, consensus 89c
Reports Q2 revenue $1.87B, consensus $1.85B.
07:22 EDTNOKNokia sees 2014 non-IFRS operating margin at or slightly above range
Subscribe for More Information
07:03 EDTABCAmerisourceBergen now sees FY14 adjusted continuing ops EPS $3.89-$3.94
Consensus is $3.73. Sees FY14 revenue growth in the 35% range, consensus $116.72B. The company says "Adjusted operating margin is expected to decline in the high-teens basis points range due to the onboarding of significant new lower margin business and growth in brand pharmaceutical business with our large customers. We expect free cash flow to be in the high end of the range of $500 to $700 million, with capital expenditures in the $275 million range, and to spend approximately $500 million in share repurchases, subject to market conditions."
07:02 EDTABCAmerisourceBergen reports Q3 continuing ops EPS $1.01, consensus 92c
Reports Q3 revenue $30.35B, consensus $29.25B.
05:39 EDTNOKNokia reports Q2 Non-IFRS EPS EUR 0.06 vs. EUR 0.05 last year
Subscribe for More Information
July 23, 2014
15:30 EDTCELGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
09:41 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL NFLX FB MSFT CELG TWTR TSLA VALE CNW
July 22, 2014
07:12 EDTCELGCelgene has upper hand in Revlimid case, says Bernstein
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use